fda regulations tirzepatide Compounded Tirzepatide: Understanding Status & Safety – PlexusDx FDA Ban on Compounded GLP-1

Purpose-built for physicians GLP-1s may reduce cardiovascular risk in rheumatoid arthritis treated with JAK inhibitors GLP-1 receptor agonists may significantly reduce the risk for cardiovascular events in patients with rheumatoid arthritis treated with Janus kinase inhibitors, according to data presented at the EULAR 2025 Congress

-

The high price point of these medications creates a significant barrier for many who could benefit immensely

Safety Considerations and Who Should Avoid Tirzepatide The most common side effects reported in trials were gastrointestinalnausea, vomiting, diarrhea, and constipationtypically mild to moderate and improving over time

478 (12): 1925 Ishii T, Shimpo Y, Matsuoka Y, et al